Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Share:
Related BMY
Watch These 10 Huge Call Purchases In Wednesday Trade
AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And Opdivo + Yervoy Regimen
Bristol-Myers and Janssen Biotech team up in lung cancer (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Latest Ratings for BMY

DateFirmActionFromTo
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold
May 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!